- Home
- ICON vs GOVX Comparison
ICON vs GOVX Comparison
Compare ICON & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICON | GOVX |
|---|---|---|
| Founded | 2023 | 2001 |
| Country | Greece | United States |
| Employees | N/A | 19 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ICON | GOVX |
|---|---|---|
| Price | $1.05 | $0.75 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 62.2K | ★ 209.4K |
| Earning Date | 02-24-2026 | 04-15-2026 |
| Dividend Yield | ★ 4754.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.33 | N/A |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.12 |
| 52 Week High | $4.23 | $4.40 |
Technical Indicators
Market Signals| Indicator | ICON | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 32.03 |
| Support Level | N/A | $0.64 |
| Resistance Level | N/A | $2.00 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 21.30 |
Price Performance
Historical ComparisonAbout ICON Icon Energy Corp.
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.